Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular Carcinoma

1 Jan 2025

Abstract excerpt

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC), the dominant form of liver cancer, is a leading cause of cancer death worldwide. Sorafenib and lenvatinib have long been the 2 limited options of first-line treatments for patients with unresectable advanced HCC. However, the single-drug treatment strategy only shows modest survival benefit, mostly because of the survival ability of cancer cells to activate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Hepatocellular Carcinoma Treatment and Prognosis
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40120675
DOI: 10.1016/j.jcmgh.2025.101502

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular CarcinomaPMID 40120675Read ↗

Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistanceSemantic proximity Read ↗

CRISPR/Cas9 screening reveals that ASB2 inhibits p53-dependent ferroptosis to mediates Lenvatinib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Combination therapy for HCC: from CRISPR screening to the design of clinical therapiesSemantic proximity Read ↗

Systematic decoding of the resistance mechanisms and therapeutic vulnerabilities in TKI-resistant hepatocellular carcinomaSemantic proximity Read ↗

Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2Semantic proximity Read ↗

Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.Semantic proximity Read ↗

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinomaSemantic proximity Read ↗

In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinomaSemantic proximity Read ↗

New strategies for targeting drug combinations to overcome mutation-driven drug resistance.Semantic proximity Read ↗

Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinomaSemantic proximity Read ↗

Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.Semantic proximity Read ↗

MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.